Leonard E. Post Sells 1,000 Shares of CG Oncology (NASDAQ:CGON) Stock

Key Points

• CG Oncology's Director Leonard Post sold 1,000 shares at an average price of $35.10, totaling $35,100, as disclosed in a regulatory filing.
• The stock price of CG Oncology increased by 3.4% on the following trading day, reaching $35.76, with trading volume above average.
• Analysts have mixed ratings for CG Oncology, with the consensus being a "Moderate Buy" and a price target of $53.91, although some brokerages have issued a "sell" rating.

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $35.10, for a total transaction of $35,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Leonard E. Post also recently made the following trade(s):

• On Thursday, July 17th, Leonard E. Post sold 2,000 shares of CG Oncology stock. The shares were sold at an average price of $28.00, for a total transaction of $56,000.00.

CG Oncology Stock Performance

CG Oncology stock traded down $1.92 during mid-day trading on Friday, hitting $36.90. 2,019,030 shares of the company traded hands, compared to its average volume of 1,086,112. The stock has a market cap of $2.81 billion, a price-to-earnings ratio of -20.85 and a beta of 0.87. CG Oncology, Inc. has a one year low of $14.80 and a one year high of $40.47. The stock has a fifty day moving average price of $28.21 and a 200-day moving average price of $25.94.

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative return on equity of 19.37% and a negative net margin of 15,945.17%. Sell-side analysts predict that CG Oncology, Inc. will post -1.31 EPS for the current year.

Hedge Funds Weigh In On CG Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in CGON. Wellington Management Group LLP grew its stake in shares of CG Oncology by 274.4% during the fourth quarter. Wellington Management Group LLP now owns 1,910,470 shares of the company's stock worth $54,792,000 after acquiring an additional 1,400,251 shares during the last quarter. Bank of America Corp DE grew its stake in shares of CG Oncology by 409.9% during the second quarter. Bank of America Corp DE now owns 1,736,769 shares of the company's stock worth $45,156,000 after acquiring an additional 1,396,170 shares during the last quarter. Candriam S.C.A. purchased a new stake in shares of CG Oncology during the second quarter worth about $19,854,000. Millennium Management LLC grew its stake in shares of CG Oncology by 139.4% during the first quarter. Millennium Management LLC now owns 596,056 shares of the company's stock worth $14,597,000 after acquiring an additional 347,055 shares during the last quarter. Finally, Alliancebernstein L.P. grew its stake in shares of CG Oncology by 15.0% during the second quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company's stock worth $56,270,000 after acquiring an additional 281,637 shares during the last quarter. Hedge funds and other institutional investors own 26.56% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on CGON. Royal Bank Of Canada lowered their target price on shares of CG Oncology from $68.00 to $53.00 and set an "outperform" rating on the stock in a research note on Wednesday, July 16th. The Goldman Sachs Group raised CG Oncology to a "strong-buy" rating and set a $40.00 price objective for the company in a research note on Thursday, July 10th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $75.00 price objective on shares of CG Oncology in a report on Monday, September 8th. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a report on Monday, September 15th. Finally, Zacks Research raised shares of CG Oncology from a "strong sell" rating to a "hold" rating in a report on Monday, September 1st. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $56.00.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.